Century Therapeutics, Inc. (NASDAQ:IPSC) to Post FY2024 Earnings of ($2.70) Per Share, HC Wainwright Forecasts

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) – Equities research analysts at HC Wainwright issued their FY2024 EPS estimates for Century Therapeutics in a research report issued on Friday, March 17th. HC Wainwright analyst M. Kapoor expects that the company will earn ($2.70) per share for the year. HC Wainwright currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Century Therapeutics’ current full-year earnings is ($1.93) per share.

Other equities research analysts have also recently issued reports about the company. Bank of America lowered their target price on Century Therapeutics from $23.00 to $20.00 in a research note on Friday. EF Hutton Acquisition Co. I reissued a “buy” rating and set a $16.00 price objective on shares of Century Therapeutics in a report on Thursday. SVB Leerink reduced their target price on shares of Century Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, January 6th. Chardan Capital started coverage on shares of Century Therapeutics in a research note on Tuesday, December 27th. They set a “buy” rating and a $19.00 price target for the company. Finally, Piper Sandler reduced their price objective on shares of Century Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, January 6th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Century Therapeutics Stock Performance

Want More Great Investing Ideas?

IPSC stock opened at $3.86 on Monday. The company has a 50 day moving average price of $4.53 and a 200 day moving average price of $7.66. Century Therapeutics has a fifty-two week low of $3.54 and a fifty-two week high of $14.02. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.44 and a quick ratio of 13.44. The stock has a market capitalization of $227.62 million, a PE ratio of -1.69 and a beta of 0.69.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its position in shares of Century Therapeutics by 27.8% during the third quarter. Tower Research Capital LLC TRC now owns 4,157 shares of the company’s stock worth $41,000 after purchasing an additional 904 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Century Therapeutics by 11.2% in the first quarter. Goldman Sachs Group Inc. now owns 20,746 shares of the company’s stock valued at $261,000 after buying an additional 2,091 shares in the last quarter. American International Group Inc. lifted its stake in Century Therapeutics by 37.1% in the first quarter. American International Group Inc. now owns 8,604 shares of the company’s stock valued at $108,000 after buying an additional 2,328 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Century Therapeutics by 3.7% in the fourth quarter. JPMorgan Chase & Co. now owns 65,461 shares of the company’s stock valued at $335,000 after buying an additional 2,360 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Century Therapeutics by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 153,323 shares of the company’s stock worth $787,000 after acquiring an additional 2,976 shares in the last quarter. Institutional investors and hedge funds own 35.81% of the company’s stock.

Century Therapeutics Company Profile

(Get Rating)

Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.